Low and High Flow Suctioning in Intubated Infants
Launched by COLUMBIA UNIVERSITY · May 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different methods of suctioning the airways of intubated infants who are having trouble breathing. The researchers want to compare a new suction device called EXSALTA to the standard suction method used in hospitals. They will monitor how these methods affect the infants' heart rate, oxygen levels, and brain oxygenation. The goal is to see if using the EXSALTA device results in less variation in these important measures compared to the standard method.
To participate in this study, infants must be preterm or term babies weighing more than 1000 grams (which is about 2.2 pounds) and receiving suctioning through a breathing tube. However, infants with certain heart conditions or heart rhythm problems will not be included. If eligible, participants can expect to undergo both suctioning methods during their care in the NICU, helping researchers understand which method might be better for their health. The study is currently recruiting participants, and all infants, regardless of gender, are welcome to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Preterm and term infants with birth weight more than 1000g receiving ETT suctioning
- Exclusion Criteria:
- • Infants with cyanotic congenital heart disease and cardiac rhythm disorders (arrythmias) will be excluded from the study.
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Rakesh Sahni, MD
Principal Investigator
Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported